For years, some of the most effective medications for weight management have required a weekly injection.
That has officially changed.
We now have FDA-approved oral GLP-1 medications specifically for weight management, including Wegovy® tablets and Lilly’s newer Foundayo™ (orforglipron).
For many patients, this could mean accessing highly effective medical weight management without ever needing an injection.
But while both are pills, they are not the same medication—and understanding the differences is important.
Meet the New Generation of GLP-1 Pills
Wegovy® Pill: Semaglutide Without the Injection
The Wegovy pill contains semaglutide, the same GLP-1 medication used in injectable Wegovy.
In the OASIS 4 clinical trial, people who remained on treatment achieved an average weight loss of approximately 16.6% of their starting body weight over 64 weeks. In the analysis that included participants regardless of whether they remained on treatment, average weight loss was approximately 13.6%.
That puts the effectiveness of oral Wegovy in a range approaching what many patients have come to expect from some injectable GLP-1 medications.
However, oral semaglutide requires more specific instructions around how the medication is taken to allow proper absorption.
Foundayo™: A Completely Different Type of GLP-1 Pill
Foundayo is the brand name for orforglipron, Lilly’s newer once-daily oral GLP-1 medication.
Unlike semaglutide, Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist. One of its biggest practical advantages is simplicity: it can be taken at any time of day without having to plan the dose around food or water.
In the pivotal ATTAIN-1 clinical trial, patients taking the highest dose lost an average of approximately 27 pounds, with clinical studies showing average weight reductions in the range of roughly 11% to 12% depending on the analysis and treatment group.
That may be less average weight loss than seen with oral Wegovy in their respective clinical trials, but Foundayo offers something many patients may value enormously:
- Convenience.
- No injection.
- No refrigeration.
- No special timing around meals or liquids.
Wegovy Pill vs. Foundayo Pill: What’s the Difference?
Here is the simplest way to think about the two:
Wegovy Pill
- Active medication: Semaglutide
- Medication class: GLP-1 receptor agonist
- Taken: Once daily
- Clinical trial weight loss: Up to approximately 16.6% average weight loss when treatment was followed
- Major advantage: Strong weight-loss efficacy and extensive clinical experience with semaglutide
- Consideration: More specific dosing and absorption requirements
Foundayo
- Active medication: Orforglipron
- Medication class: Oral small-molecule GLP-1 receptor agonist
- Taken: Once daily
- Clinical trial weight loss: Approximately 11% to 12% average weight loss at higher doses in reported trials
- Major advantage: Can be taken at essentially any time of day without food or water restrictions
- Consideration: It is a newer medication with less long-term real-world experience than semaglutide
One medication is not automatically “better” than the other.
The better medication is the one that works best for the individual patient.
How Do the Pills Compare With the Injections?
This is probably the question I will hear most often:
“Doc, should I take the pill or the shot?”
The answer depends on your individual goals and circumstances.
Injectable medications such as Zepbound® and Wegovy® remain excellent options and, depending on the medication and patient, may produce greater weight loss than some oral treatments.
But the new pills offer several potential advantages:
- No needles.
- No weekly injections.
- Easier storage and travel.
Potentially lower manufacturing costs and improved access over time.
For some people, taking a daily pill may also simply feel more familiar and comfortable.
On the other hand, some patients may actually prefer taking a medication once a week rather than remembering a pill every day.
That is why the future of obesity treatment will not be about choosing one medication for everyone.
It will be about having more choices and better personalization.
More Options Are Coming—and That Is Great News for Patients
For decades, physicians had relatively few effective medications to offer patients struggling with obesity.
Today, we have multiple injectable GLP-1 and GIP-based therapies, new oral medications, and an expanding pipeline of next-generation treatments.
This is one of the most exciting changes I have witnessed in obesity medicine.
But more medications can also create more confusion.
Should you take Wegovy?
Foundayo?
Zepbound?
Another medication?
Or perhaps no medication at all?
The answer should not come from a social media influencer, an advertisement, or simply choosing whichever medication happens to be most popular.
It should come from understanding your individual health, goals, medical history, body composition, lifestyle and response to treatment.
The Medication Is Only One Part of Successful Weight Management
At Achieve Health & Weight Loss, we believe successful treatment is about much more than simply getting a prescription.
Whether your treatment involves Wegovy, Foundayo, Zepbound or another appropriate option, medication should be one tool within a comprehensive program.
Our approach combines physician-supervised medical care with personalized coaching, nutrition guidance, activity recommendations, accountability and ongoing monitoring.
We also focus on something that is too often overlooked during weight loss:
What are you actually losing?
Losing 30 pounds on the scale is very different from losing 30 pounds while preserving as much lean muscle as possible.
The goal should not simply be to become a smaller version of yourself.
The goal is to lose excess fat, preserve muscle and become healthier, stronger and more confident.
Which GLP-1 Pill Is Right for You?
For some patients, the strong clinical results and established history of semaglutide may make the Wegovy pill attractive.
For others, the simplicity and convenience of taking Foundayo without food or water restrictions may be a significant advantage.
Others may still be better candidates for an injectable treatment.
The exciting news is that patients now have more legitimate, FDA-approved options than ever before.
The future of weight management is not just another medication.
It is having the ability to choose the right medication for the right patient at the right time.
And that future is already here.
